We’ll help you find the highest quality medicine that you need.
Pomalyst
is indicated for patients with multiple myeloma who have received at least two prior therapies including Lenalidomide and Bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Manufactured by: Celgene Corp
Active Ingredient(s): Pomalidomide
Dosage Form: Capsule, oral
Strength: 1 mg, 2 mg, 3 mg and 4 mg
FDA approved: February 8, 2013
More information about Pomalyst:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf